Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2020-2026) – by Drug Class, Indications, Distribution Channels, and Region.

Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2020 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6% during the forecast period. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.Global Cardiovascular Drugs Market To know about the Research Methodology:-Request Free Sample Report The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data, and projections with a suitable set of assumptions and methodology. The report also helps in understanding Cardiovascular Drugs' market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in near future to emerging segment in Cardiovascular Drugs market. The global cardiovascular disease drug market is expected to witness a high growth mainly owing to rising incidences of people suffering from cardiovascular disease. Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular diseases are one of the leading causes of death worldwide. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (heart attack). Other Cardiovascular diseases include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis. Based on the Drug Class, the anti-coagulants agents' segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by the anti-hyperlipidemia segment. Outline of new anti-hyperlipidemia drug such as PCSK9 Inhibitor (Praluent) and increasing incidences of hyperlipidemia is likely to boost expansion of the segment. Based on the Indications, hypertension was the leading revenue generating segment in 2017, and it is likely to continue its dominance during the forecast period. Antihypertensives are a class of drugs that are used to treat hypertension. Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Based on the Distribution Channels, Hospital Pharmacies was the leading distribution channel in 2017. Cardiovascular diseases are responsible for nearly 30% of the world’s deaths annually. Thus, the volume of therapeutic as well as diagnostics products dispensed by hospital pharmacies for cardiovascular diseases is high. Some of the key factors working in favor of the global hospital pharmaceuticals market are the vast rise in prevalence of chronic diseases such as cancer, diabetes, and a number of cardiovascular conditions, and the rising expenditure on healthcare across emerging economies. Online and Retail Pharmacies is projected to gain market share during the forecast period. Geographically, North America held major shares of the global cardiovascular drugs market in 2016. Asia Pacific market is projected to gain market share during the forecast period and is possible to be a key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost the market growth in South America, and the Middle East & Africa.

Scope of the Global Cardiovascular Drugs Markets: Inquire before buying

Global Cardiovascular Drugs Markets, by Drug Class

• Anti hyperlipidemics • Anti-hypertensives • Anti-coagulants • Anti-fibrinolytics • Anti-arrhythmic

Global Cardiovascular Drugs Markets, by Indications

• Hypertension • Hyperlipidemia • Coronary Artery Disease • Peripheral Artery Disease • Arrhythmia • Others

Global Cardiovascular Drugs Markets, by Distribution Channels

• Hospital Pharmacies • Online Pharmacies • Retail Pharmacies

Global Cardiovascular Drugs Market, by Region

• North America • Europe • Asia-Pacific • Middle East & Africa • South America

Key Players Operating In the Cardiovascular Drugs Market:

• AstraZeneca plc. • Bayer AG, Merck & Co., Inc. • Sanofi • Pfizer • Eli Lilly & Company • Sanofi • Bayer Corp. • Bristol-Myers Squibb Co. • Daiichi Sankyo • Johnson & Johnson • Gilead Sciences Inc. • Par Pharmaceutical • United Therapeutics • Nippon Shinyaku Co. Ltd. • Lupin Atlantis Holdings • Silvergate Pharmaceuticals Inc. • TSH Biopharm Corp. • Novartis • Relypsa • Vectus Biosystems Ltd. • Phasebio Pharmaceuticals • Ablative Solutions • Mylan Specialty • Curemark • Takeda Pharmaceutical Co.

Global Cardiovascular Drugs Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary 3.1. Global Cardiovascular Drugs Market Size, by Market Volume (Units) And Market Value (US$ Bn), By Region 4. Market Overview 4.1. Introduction 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side And Demand Side Indicators 6. Global Cardiovascular Drugs Market Analysis and Forecast 6.1. Global Cardiovascular Drugs Market Analysis and Forecast 6.2. Global Cardiovascular Drugs Market Size& Y-o-Y Growth Analysis 6.2.1. North America 6.2.2. Europe 6.2.3. Asia Pacific 6.2.4. Middle East & Africa 6.2.5. South America 7. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Drug Class 7.4. Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class 7.5. Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class 8. Global Cardiovascular Drugs Market Analysis and Forecast, by Indications 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Indications 8.4. Global Cardiovascular Drugs Market Value Share Analysis, by Indications 8.5. Global Cardiovascular Drugs Market Attractiveness Analysis, by Indications 9. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channels 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Distribution Channels 9.4. Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 9.5. Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channels 10. Global Cardiovascular Drugs Market Analysis, by Region 10.1. Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Region 10.2. Global Cardiovascular Drugs Market Value Share Analysis, by Region 10.3. Global Cardiovascular Drugs Market Attractiveness Analysis, by Region 11. North America Cardiovascular Drugs Market Analysis 11.1. North America Cardiovascular Drugs Market Overview 11.2. North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class 11.3. North America Cardiovascular Drugs Market Forecast, by Drug Class 11.3.1. Anti hyperlipidemics 11.3.2. Anti-hypertensives 11.3.3. Anti-coagulants 11.3.4. Anti-fibrinolytics 11.3.5. Anti-arrhythmic 11.4. North America Cardiovascular Drugs Market Value Share Analysis, by Indications 11.5. North America Cardiovascular Drugs Market Forecast, by Indications 11.5.1. Hypertension 11.5.2. Hyperlipidemia 11.5.3. Coronary Artery Disease 11.5.4. Peripheral Artery Disease 11.5.5. Arrhythmia 11.5.6. Others 11.6. North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 11.7. North America Cardiovascular Drugs Market Forecast, by Distribution Channels 11.7.1. Hospital Pharmacies 11.7.2. Online Pharmacies 11.7.3. Retail Pharmacies 11.8. North America Cardiovascular Drugs Market Value Share Analysis, by Country 11.9. North America Cardiovascular Drugs Market Forecast, by Country 11.9.1. U.S 11.9.2. Canada 11.10. North America Cardiovascular Drugs Market Analysis, by Country 11.11. U.S. Cardiovascular Drugs Market Forecast, by Drug Class 11.11.1. Anti hyperlipidemics 11.11.2. Anti-hypertensives 11.11.3. Anti-coagulants 11.11.4. Anti-fibrinolytics 11.11.5. Anti-arrhythmic 11.12. U.S. Cardiovascular Drugs Market Forecast, by Indications 11.12.1. Hypertension 11.12.2. Hyperlipidemia 11.12.3. Coronary Artery Disease 11.12.4. Peripheral Artery Disease 11.12.5. Arrhythmia 11.13. Others U.S. Cardiovascular Drugs Market Forecast, by Distribution Channels 11.13.1. Hospital Pharmacies 11.13.2. Online Pharmacies 11.13.3. Retail Pharmacies 11.14. Canada Cardiovascular Drugs Market Forecast, by Drug Class 11.14.1. Anti hyperlipidemics 11.14.2. Anti-hypertensives 11.14.3. Anti-coagulants 11.14.4. Anti-fibrinolytics 11.14.5. Anti-arrhythmic 11.15. Canada Cardiovascular Drugs Market Forecast, by Indications 11.15.1. Hypertension 11.15.2. Hyperlipidemia 11.15.3. Coronary Artery Disease 11.15.4. Peripheral Artery Disease 11.15.5. Arrhythmia 11.16. Others Canada Cardiovascular Drugs Market Forecast, by Distribution Channels 11.16.1. Hospital Pharmacies 11.16.2. Online Pharmacies 11.16.3. Retail Pharmacies 11.17. North America Cardiovascular Drugs Market Attractiveness Analysis 11.17.1. By Drug Class 11.17.2. By Indications 11.17.3. By Distribution Channels 11.18. PEST Analysis 11.19. Key Trends 11.20. Key Developments 12. Europe Cardiovascular Drugs Market Analysis 12.1. Europe Cardiovascular Drugs Market Overview 12.2. Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class 12.3. Europe Cardiovascular Drugs Market Forecast, by Drug Class 12.3.1. Anti hyperlipidemics 12.3.2. Anti-hypertensives 12.3.3. Anti-coagulants 12.3.4. Anti-fibrinolytics 12.3.5. Anti-arrhythmic 12.4. Europe Cardiovascular Drugs Market Value Share Analysis, by Indications 12.5. Europe Cardiovascular Drugs Market Forecast, by Indications 12.5.1. Hypertension 12.5.2. Hyperlipidemia 12.5.3. Coronary Artery Disease 12.5.4. Peripheral Artery Disease 12.5.5. Arrhythmia 12.6. Others Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 12.7. Europe Cardiovascular Drugs Market Forecast, by Distribution Channels 12.7.1. Hospital Pharmacies 12.7.2. Online Pharmacies 12.7.3. Retail Pharmacies 12.8. Europe Cardiovascular Drugs Market Value Share Analysis, by Country 12.9. Europe Cardiovascular Drugs Market Forecast, by Country 12.9.1. Germany 12.9.2. U.K. 12.9.3. France 12.9.4. Italy 12.9.5. Spain 12.9.6. Rest of Europe 12.10. Europe Cardiovascular Drugs Market Analysis, by Country/ Sub-region 12.11. Germany Cardiovascular Drugs Market Forecast, by Drug Class 12.11.1. Anti hyperlipidemics 12.11.2. Anti-hypertensives 12.11.3. Anti-coagulants 12.11.4. Anti-fibrinolytics 12.11.5. Anti-arrhythmic 12.12. Germany Cardiovascular Drugs Market Forecast, by Indications 12.12.1. Hypertension 12.12.2. Hyperlipidemia 12.12.3. Coronary Artery Disease 12.12.4. Peripheral Artery Disease 12.12.5. Arrhythmia 12.13. Others Germany Cardiovascular Drugs Market Forecast, by Distribution Channels 12.13.1. Hospital Pharmacies 12.13.2. Online Pharmacies 12.13.3. Retail Pharmacies 12.14. U.K. Cardiovascular Drugs Market Forecast, by Drug Class 12.14.1. Anti hyperlipidemics 12.14.2. Anti-hypertensives 12.14.3. Anti-coagulants 12.14.4. Anti-fibrinolytics 12.14.5. Anti-arrhythmic 12.15. U.K. Cardiovascular Drugs Market Forecast, by Indications 12.15.1. Hypertension 12.15.2. Hyperlipidemia 12.15.3. Coronary Artery Disease 12.15.4. Peripheral Artery Disease 12.15.5. Arrhythmia 12.16. Others U.K. Cardiovascular Drugs Market Forecast, by Distribution Channels 12.16.1. Hospital Pharmacies 12.16.2. Online Pharmacies 12.16.3. Retail Pharmacies 12.17. France Cardiovascular Drugs Market Forecast, by Drug Class 12.17.1. Anti hyperlipidemics 12.17.2. Anti-hypertensives 12.17.3. Anti-coagulants 12.17.4. Anti-fibrinolytics 12.17.5. Anti-arrhythmic 12.18. France Cardiovascular Drugs Market Forecast, by Indications 12.18.1. Hypertension 12.18.2. Hyperlipidemia 12.18.3. Coronary Artery Disease 12.18.4. Peripheral Artery Disease 12.18.5. Arrhythmia 12.19. Others France Cardiovascular Drugs Market Forecast, by Distribution Channels 12.19.1. Hospital Pharmacies 12.19.2. Online Pharmacies 12.19.3. Retail Pharmacies 12.20. Italy Cardiovascular Drugs Market Forecast, by Drug Class 12.20.1. Anti hyperlipidemics 12.20.2. Anti-hypertensives 12.20.3. Anti-coagulants 12.20.4. Anti-fibrinolytics 12.20.5. Anti-arrhythmic 12.21. Italy Cardiovascular Drugs Market Forecast, by Indications 12.21.1. Hypertension 12.21.2. Hyperlipidemia 12.21.3. Coronary Artery Disease 12.21.4. Peripheral Artery Disease 12.21.5. Arrhythmia 12.22. Others Italy Cardiovascular Drugs Market Forecast, by Distribution Channels 12.22.1. Hospital Pharmacies 12.22.2. Online Pharmacies 12.22.3. Retail Pharmacies 12.23. Spain Cardiovascular Drugs Market Forecast, by Drug Class 12.23.1. Anti hyperlipidemics 12.23.2. Anti-hypertensives 12.23.3. Anti-coagulants 12.23.4. Anti-fibrinolytics 12.23.5. Anti-arrhythmic 12.24. Spain Cardiovascular Drugs Market Forecast, by Indications 12.24.1. Hypertension 12.24.2. Hyperlipidemia 12.24.3. Coronary Artery Disease 12.24.4. Peripheral Artery Disease 12.24.5. Arrhythmia 12.25. Others Spain Cardiovascular Drugs Market Forecast, by Distribution Channels 12.25.1. Hospital Pharmacies 12.25.2. Online Pharmacies 12.25.3. Retail Pharmacies 12.26. Rest of Europe Cardiovascular Drugs Market Forecast, by Drug Class 12.26.1. Anti hyperlipidemics 12.26.2. Anti-hypertensives 12.26.3. Anti-coagulants 12.26.4. Anti-fibrinolytics 12.26.5. Anti-arrhythmic 12.27. Rest of Europe Cardiovascular Drugs Market Forecast, by Indications 12.27.1. Hypertension 12.27.2. Hyperlipidemia 12.27.3. Coronary Artery Disease 12.27.4. Peripheral Artery Disease 12.27.5. Arrhythmia 12.27.6. Others 12.28. Rest of Europe Cardiovascular Drugs Market Forecast, by Distribution Channels 12.28.1. Hospital Pharmacies 12.28.2. Online Pharmacies 12.28.3. Retail Pharmacies 12.29. Europe Cardiovascular Drugs Market Attractiveness Analysis 12.29.1. By Drug Class 12.29.2. By Indications 12.29.3. By Distribution Channels 12.30. PEST Analysis 12.31. Key Trends 12.32. Key Developments 13. Asia Pacific Cardiovascular Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Cardiovascular Drugs Market Overview 13.3. Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Cardiovascular Drugs Market Forecast, by Drug Class 13.4.1. Anti hyperlipidemics 13.4.2. Anti-hypertensives 13.4.3. Anti-coagulants 13.4.4. Anti-fibrinolytics 13.4.5. Anti-arrhythmic 13.5. Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indications 13.6. Asia Pacific Cardiovascular Drugs Market Forecast, by Indications 13.6.1. Hypertension 13.6.2. Hyperlipidemia 13.6.3. Coronary Artery Disease 13.6.4. Peripheral Artery Disease 13.6.5. Arrhythmia 13.7. Others Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 13.8. Asia Pacific Cardiovascular Drugs Market Forecast, by Distribution Channels 13.8.1. Hospital Pharmacies 13.8.2. Online Pharmacies 13.8.3. Retail Pharmacies 13.9. Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Cardiovascular Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Cardiovascular Drugs Market Analysis, by Country/ Sub-region 13.12. China Cardiovascular Drugs Market Forecast, by Drug Class 13.12.1. Anti hyperlipidemics 13.12.2. Anti-hypertensives 13.12.3. Anti-coagulants 13.12.4. Anti-fibrinolytics 13.12.5. Anti-arrhythmic 13.13. China Cardiovascular Drugs Market Forecast, by Indications 13.13.1. Hypertension 13.13.2. Hyperlipidemia 13.13.3. Coronary Artery Disease 13.13.4. Peripheral Artery Disease 13.13.5. Arrhythmia 13.14. Others China Cardiovascular Drugs Market Forecast, by Distribution Channels 13.14.1. Hospital Pharmacies 13.14.2. Online Pharmacies 13.14.3. Retail Pharmacies 13.15. India Cardiovascular Drugs Market Forecast, by Drug Class 13.15.1. Anti hyperlipidemics 13.15.2. Anti-hypertensives 13.15.3. Anti-coagulants 13.15.4. Anti-fibrinolytics 13.15.5. Anti-arrhythmic 13.16. India Cardiovascular Drugs Market Forecast, by Indications 13.16.1. Hypertension 13.16.2. Hyperlipidemia 13.16.3. Coronary Artery Disease 13.16.4. Peripheral Artery Disease 13.16.5. Arrhythmia 13.17. Others India Cardiovascular Drugs Market Forecast, by Distribution Channels 13.17.1. Hospital Pharmacies 13.17.2. Online Pharmacies 13.17.3. Retail Pharmacies 13.18. Japan Cardiovascular Drugs Market Forecast, by Drug Class 13.18.1. Anti hyperlipidemics 13.18.2. Anti-hypertensives 13.18.3. Anti-coagulants 13.18.4. Anti-fibrinolytics 13.18.5. Anti-arrhythmic 13.19. Japan Cardiovascular Drugs Market Forecast, by Indications 13.19.1. Hypertension 13.19.2. Hyperlipidemia 13.19.3. Coronary Artery Disease 13.19.4. Peripheral Artery Disease 13.19.5. Arrhythmia 13.20. Others Japan Cardiovascular Drugs Market Forecast, by Distribution Channels 13.20.1. Hospital Pharmacies 13.20.2. Online Pharmacies 13.20.3. Retail Pharmacies 13.21. ASEAN Cardiovascular Drugs Market Forecast, by Drug Class 13.21.1. Anti hyperlipidemics 13.21.2. Anti-hypertensives 13.21.3. Anti-coagulants 13.21.4. Anti-fibrinolytics 13.21.5. Anti-arrhythmic 13.22. ASEAN Cardiovascular Drugs Market Forecast, by Indications 13.22.1. Hypertension 13.22.2. Hyperlipidemia 13.22.3. Coronary Artery Disease 13.22.4. Peripheral Artery Disease 13.22.5. Arrhythmia 13.23. Others ASEAN Cardiovascular Drugs Market Forecast, by Distribution Channels 13.23.1. Hospital Pharmacies 13.23.2. Online Pharmacies 13.23.3. Retail Pharmacies 13.24. Rest of Asia Pacific Cardiovascular Drugs Market Forecast, by Drug Class 13.24.1. Anti hyperlipidemics 13.24.2. Anti-hypertensives 13.24.3. Anti-coagulants 13.24.4. Anti-fibrinolytics 13.24.5. Anti-arrhythmic 13.25. Rest of Asia Pacific Cardiovascular Drugs Market Forecast, by Indications 13.25.1. Hypertension 13.25.2. Hyperlipidemia 13.25.3. Coronary Artery Disease 13.25.4. Peripheral Artery Disease 13.25.5. Arrhythmia 13.26. Others Rest of Asia Pacific Cardiovascular Drugs Market Forecast, by Distribution Channels 13.26.1. Hospital Pharmacies 13.26.2. Online Pharmacies 13.26.3. Retail Pharmacies 13.27. Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Indications 13.27.3. By Distribution Channels 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Cardiovascular Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Cardiovascular Drugs Market Overview 14.3. Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Cardiovascular Drugs Market Forecast, by Drug Class 14.4.1. Anti hyperlipidemics 14.4.2. Anti-hypertensives 14.4.3. Anti-coagulants 14.4.4. Anti-fibrinolytics 14.4.5. Anti-arrhythmic 14.5. Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indications 14.6. Middle East & Africa Cardiovascular Drugs Market Forecast, by Indications 14.6.1. Hypertension 14.6.2. Hyperlipidemia 14.6.3. Coronary Artery Disease 14.6.4. Peripheral Artery Disease 14.6.5. Arrhythmia 14.7. Others Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 14.8. Middle East & Africa Cardiovascular Drugs Market Forecast, by Distribution Channels 14.8.1. Hospital Pharmacies 14.8.2. Online Pharmacies 14.8.3. Retail Pharmacies 14.9. Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Cardiovascular Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Cardiovascular Drugs Market Analysis, by Country/ Sub-region 14.12. GCC Cardiovascular Drugs Market Forecast, by Drug Class 14.12.1. Anti hyperlipidemics 14.12.2. Anti-hypertensives 14.12.3. Anti-coagulants 14.12.4. Anti-fibrinolytics 14.12.5. Anti-arrhythmic 14.13. GCC Cardiovascular Drugs Market Forecast, by Indications 14.13.1. Hypertension 14.13.2. Hyperlipidemia 14.13.3. Coronary Artery Disease 14.13.4. Peripheral Artery Disease 14.13.5. Arrhythmia 14.14. Others GCC Cardiovascular Drugs Market Forecast, by Distribution Channels 14.14.1. Hospital Pharmacies 14.14.2. Online Pharmacies 14.14.3. Retail Pharmacies 14.15. South Africa Cardiovascular Drugs Market Forecast, by Drug Class 14.15.1. Anti hyperlipidemics 14.15.2. Anti-hypertensives 14.15.3. Anti-coagulants 14.15.4. Anti-fibrinolytics 14.15.5. Anti-arrhythmic 14.16. South Africa Cardiovascular Drugs Market Forecast, by Indications 14.16.1. Hypertension 14.16.2. Hyperlipidemia 14.16.3. Coronary Artery Disease 14.16.4. Peripheral Artery Disease 14.16.5. Arrhythmia 14.17. Others South Africa Cardiovascular Drugs Market Forecast, by Distribution Channels 14.17.1. Hospital Pharmacies 14.17.2. Online Pharmacies 14.17.3. Retail Pharmacies 14.18. Rest of Middle East & Africa Cardiovascular Drugs Market Forecast, by Drug Class 14.18.1. Anti hyperlipidemics 14.18.2. Anti-hypertensives 14.18.3. Anti-coagulants 14.18.4. Anti-fibrinolytics 14.18.5. Anti-arrhythmic 14.19. Rest of Middle East & Africa Cardiovascular Drugs Market Forecast, by Indications 14.19.1. Hypertension 14.19.2. Hyperlipidemia 14.19.3. Coronary Artery Disease 14.19.4. Peripheral Artery Disease 14.19.5. Arrhythmia 14.20. Others Rest of Middle East & Africa Cardiovascular Drugs Market Forecast, by Distribution Channels 14.20.1. Hospital Pharmacies 14.20.2. Online Pharmacies 14.20.3. Retail Pharmacies 14.21. Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Indications 14.21.3. By Distribution Channels 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Cardiovascular Drugs Market Analysis 15.1. Key Findings 15.2. South America Cardiovascular Drugs Market Overview 15.3. South America Cardiovascular Drugs Market Value Share Analysis, by Drug Class 15.4. South America Cardiovascular Drugs Market Forecast, by Drug Class 15.4.1. Anti hyperlipidemics 15.4.2. Anti-hypertensives 15.4.3. Anti-coagulants 15.4.4. Anti-fibrinolytics 15.4.5. Anti-arrhythmic 15.5. South America Cardiovascular Drugs Market Value Share Analysis, by Indications 15.6. South America Cardiovascular Drugs Market Forecast, by Indications 15.6.1. Hypertension 15.6.2. Hyperlipidemia 15.6.3. Coronary Artery Disease 15.6.4. Peripheral Artery Disease 15.6.5. Arrhythmia 15.7. Others South America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channels 15.8. South America Cardiovascular Drugs Market Forecast, by Distribution Channels 15.8.1. Hospital Pharmacies 15.8.2. Online Pharmacies 15.8.3. Retail Pharmacies 15.9. South America Cardiovascular Drugs Market Value Share Analysis, by Country 15.10. South America Cardiovascular Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of Latin America 15.11. South America Cardiovascular Drugs Market Analysis, by Country/ Sub-region 15.12. Brazil Cardiovascular Drugs Market Forecast, by Drug Class 15.12.1. Anti hyperlipidemics 15.12.2. Anti-hypertensives 15.12.3. Anti-coagulants 15.12.4. Anti-fibrinolytics 15.12.5. Anti-arrhythmic 15.13. Brazil Cardiovascular Drugs Market Forecast, by Indications 15.13.1. Hypertension 15.13.2. Hyperlipidemia 15.13.3. Coronary Artery Disease 15.13.4. Peripheral Artery Disease 15.13.5. Arrhythmia 15.14. Others Brazil Cardiovascular Drugs Market Forecast, by Distribution Channels 15.14.1. Hospital Pharmacies 15.14.2. Online Pharmacies 15.14.3. Retail Pharmacies 15.15. Mexico Cardiovascular Drugs Market Forecast, by Drug Class 15.15.1. Anti hyperlipidemics 15.15.2. Anti-hypertensives 15.15.3. Anti-coagulants 15.15.4. Anti-fibrinolytics 15.15.5. Anti-arrhythmic 15.16. Mexico Cardiovascular Drugs Market Forecast, by Indications 15.16.1. Hypertension 15.16.2. Hyperlipidemia 15.16.3. Coronary Artery Disease 15.16.4. Peripheral Artery Disease 15.16.5. Arrhythmia 15.17. Others Mexico Cardiovascular Drugs Market Forecast, by Distribution Channels 15.17.1. Hospital Pharmacies 15.17.2. Online Pharmacies 15.17.3. Retail Pharmacies 15.18. Rest of South America Cardiovascular Drugs Market Forecast, by Drug Class 15.18.1. Anti hyperlipidemics 15.18.2. Anti-hypertensives 15.18.3. Anti-coagulants 15.18.4. Anti-fibrinolytics 15.18.5. Anti-arrhythmic 15.19. Rest of South America Cardiovascular Drugs Market Forecast, by Indications 15.19.1. Hypertension 15.19.2. Hyperlipidemia 15.19.3. Coronary Artery Disease 15.19.4. Peripheral Artery Disease 15.19.5. Arrhythmia 15.20. Others Rest of South America Cardiovascular Drugs Market Forecast, by Distribution Channels 15.20.1. Hospital Pharmacies 15.20.2. Online Pharmacies 15.20.3. Retail Pharmacies 15.21. South America Cardiovascular Drugs Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Indications 15.21.3. By Distribution Channels 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.3. Company Profiles: Key Player 16.3.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.3.2. New Product Launches and Product Enhancements 16.3.3. Market Consolidation 16.3.3.1. M&A by Regions, Investment and Applications 16.3.3.2. M&A Key Players, Forward Integration and Backward Integration 16.4. Company Profiles: Key Players 16.4.1. AstraZeneca plc. 16.4.1.1. Company Overview 16.4.1.2. Financial Overview 16.4.1.3. Product Portfolio 16.4.1.4. Business Strategy 16.4.1.5. Recent Developments 16.4.2. Bayer AG, Merck & Co., Inc. 16.4.3. Sanofi 16.4.4. Pfizer 16.4.5. Eli Lilly & Company 16.4.6. Sanofi 16.4.7. Bayer Corp. 16.4.8. Bristol-Myers Squibb Co. 16.4.9. Daiichi Sankyo 16.4.10. Johnson & Johnson 16.4.11. Gilead Sciences Inc. 16.4.12. Par Pharmaceutical 16.4.13. United Therapeutics 16.4.14. Nippon Shinyaku Co. Ltd. 16.4.15. Lupin Atlantis Holdings 16.4.16. Silvergate Pharmaceuticals Inc. 16.4.17. TSH Biopharm Corp. 16.4.18. Novartis 16.4.19. Relypsa 16.4.20. Vectus Biosystems Ltd. 16.4.21. Phasebio Pharmaceuticals 16.4.22. Ablative Solutions 16.4.23. Mylan Specialty 16.4.24. Curemark 16.4.25. Takeda Pharmaceutical Co. 17. Primary Key Insights

About This Report

Report ID 26071
Category Healthcare
Published Date Feb 2019
Updated Date March 2021
Contact Us